John Garvey, a Foley Private Equity & Venture Capital Partner, moderated this session with panelists Josh Hamermesh of Molecular Insight Pharmaceuticals, Inc. and Matt Karlyn of Foley. They addressed in-licensing technology, specifically how to identify potential profit opportunities; approaching potential business partners, pre-transaction due diligence; negotiating with the licensor; and integration of the in-licensed technology into the company business operations.
Related Insights
August 14, 2025
Foley Ignite
Will the Late Summer M&A Rebound Continue into Fall?
The lazy days of summer seem to be behind us as merger and acquisition (M&A) activity is getting a jump start. A recent article in the…
August 14, 2025
Manufacturing Industry Advisor
Tariffs and Your Contracts: Why do delivery terms matter?
In light of a trade landscape rife with tariffs, companies are examining their commercial contracts to judge the exposure to increased costs of production. One area of a supply contract that cannot be overlooked when determining this type of exposure is the delivery terms for the product sale. This is because the delivery terms of a contract may identify the party responsible for payment of tariffs.
August 14, 2025
Foley Viewpoints
SEC Intensifies Scrutiny of Chief Compliance Officers
Two recent SEC enforcement actions serve as a sharp reminder that Chief Compliance Officers (CCOs) can face personal liability for what…